Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.69 |
| ▸ | RARB | P10826 | 7/20 | 0.65 |
| ▸ | RARG | P13631 | 7/20 | 0.57 |
| ▸ | RARA | P10276 | 4/20 | 0.57 |
| ▸ | RXRB | P28702 | 5/20 | 0.53 |
| ▸ | RXRG | P48443 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30701833 | 1.00 | RXRA (0.69) | RXRARARBRARGRARARXRB | |
| SCHEMBL28646163 | 0.88 | RXRA (0.59) | RXRARARBRARGRARARXRB | |
| SCHEMBL726366 | 0.85 | RXRA (0.59) | RXRARARBRARGRARARXRB | |
| SCHEMBL1073920 | 0.82 | RXRA (1.00) | RXRARARBRARGRARARXRB | |
| SCHEMBL5359740 | 0.81 | RXRA (0.71) | RXRARARBRARGRARARXRB | |
| SCHEMBL2191766 | 0.80 | RXRA (0.55) | RXRARARBRARGRARARXRB | |
| SCHEMBL2196140 | 0.80 | RXRA (0.55) | RXRARARBRARGRARARXRB | |
| SCHEMBL2196986 | 0.80 | RXRA (0.55) | RXRARARBRARGRARARXRB | |
| SCHEMBL2193183 | 0.80 | RXRA (0.81) | RXRARARBRARGRARARXRB | |
| SCHEMBL6889176 | 0.80 | RXRA (1.00) | RXRARARBRARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246900-A1 | SYNTHESIS OF TETRAHYDRONAPHTHALENOLS AND USES THEREOF | Io Therapeutics, Inc. | 2024-07-25 | — | — | US | disclosed |
| US-11976021-B2 | Synthesis of tetrahydronaphthalenols and uses thereof | Io Therapeutics, Inc. (US) | 2024-05-07 | — | — | US | disclosed |
| WO-2024006732-A1 | SYNTHESIS OF TETRAHYDRONAPHTHALENOLS AND USES THEREOF | Io Therapeutics, Inc. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230416190-A1 | SYNTHESIS OF TETRAHYDRONAPHTHALENOLS AND USES THEREOF | Io Therapeutics, Inc. | 2023-12-28 | — | — | US | disclosed |
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2345409-A1 | THERAPEUTIC AGENT FOR ADULT T-CELL LEUKEMIA | Kagoshima University (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| US-6610744-B2 | Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition | ALLERGAN, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | ALLERGAN SALES, INC. | 2002-06-20 | — | — | US | disclosed |
| US-6342602-B1 | BIND SPECIFICALLY OR SELECTIVELY TO RAR-ALPHA RECEPTORS | ALLERGAN SALES, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-0876330-B1 | ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2001-03-28 | — | — | EP | disclosed |
| US-6124455-A | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity | ALLERGAN SALES, INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6034244-A | ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; ANTICANCER AGENT | ALLERGAN SALES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-5965606-A | RETINOID RECEPTORS, 2-FLUORO-4-(2',2',4',4'-TETRAMETHYL-8'-TRIFLUOROMETHYLCHROMAN-6' -YL)CARBAMOYL BENZOIC ACID FOR TREATING MONOCYTIC LEUKEMIA | ALLERGAN SALES, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5856490-A | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity | ALLERGAN (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0869782-A2 | METHODS OF TREATMENT WITH COMPOUNDS HAVING RAR $g(a)? RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY | Vision Pharmaceuticals L.P. (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5675024-A | RETINOID RECEPTOR AGONISTS | ALLERGAN (US) | 1997-10-07 | — | — | US | disclosed |
| WO-1997024116-A2 | METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY | VISION PHARMACEUTICALS L.P. (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | RARG, RARA, RARB | RXRA 5/4885RARB 3/4885RARG 1/4885 |
| US-20240246900-A1 | SYNTHESIS OF TETRAHYDRONAPHTHALENOLS AND USES THEREOF | DHPS, LSS, CYP8B1 | RXRA 968/4885RARB 1499/4885RARG 932/4885 |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | CBR3, CD47, ATL3 | RXRA 1135/4885RARB 2945/4885RARG 2656/4885 |
| US-11976021-B2 | Synthesis of tetrahydronaphthalenols and uses thereof | DHPS, LSS, CYP8B1 | RXRA 968/4885RARB 1499/4885RARG 932/4885 |
| US-20230416190-A1 | SYNTHESIS OF TETRAHYDRONAPHTHALENOLS AND USES THEREOF | DHPS, LSS, CYP8B1 | RXRA 968/4885RARB 1499/4885RARG 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.